Role of a high throughput biodosimetry test in treatment prioritization after a nuclear incident
Authors:
Open Access
- 3 December 2018
- journal article
- research article
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 96 (1) , 57-66
Abstract
Purpose: We introduce and evaluate a high throughput biodosimetry test system (REDI-Dx) suitable for testing of thousands of potential radiation victims following a mass scale nuclear event caused by detonation of a nuclear device or a nuclear accident, as part of an overall strategy for effective medical management of the crisis. Materials and methods: The performance of a high throughput biodosimetry test was evaluated by collecting samples of both non-irradiated presumed healthy donors as well as irradiated subjects collected as part of either cancer treatment regimens or banked from previous studies. The test measures the gene expression of a set of radiation responsive genes based on the DxDirect® genomic platform. The potential diagnostic accuracy of REDI-Dx was evaluated as a predictor of actual dose of radiation. While the REDI-Dx test has been calibrated to provide a quantitative measure of actual absorbed dose, we compared the performance of the REDI-Dx test (sensitivity and specificity) as a qualitative result at the most commonly applied thresholds 2.0 Gy and 6.0 Gy. Results: The test demonstrated high specificity and lack of effect of medical conditions. Using receiver operating characteristic (ROC) curve analysis, REDI-Dx was shown to be a good predictor of actual dose for determining treatment category based on either 2.0 or 6.0 Gy, with a 98.5% sensitivity and 90% specificity for 2.0 Gy, and 92% sensitivity and 84% specificity for 6.0 Gy. Results were reproducible between clinical laboratories with an SD of 0.2 Gy for samples ≤2.0 Gy and a CV of 10.3% for samples from 2.0 to 10.0 Gy. Conclusions: Use of a biodosimetry test, like REDI-Dx test system would provide valuable information that would improve the ability to assign patients to the correct treatment category when combined with currently available biodosimetry tools, as compared to the use of existing tools alone. The REDI-Dx biodosimetry test system is for investigational use only in the U.S.A. The performance characteristics of this product have not been established.Keywords
Funding Information
- Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services (HHSO100201000001C, HHSO100201600034C)
This publication has 8 references indexed in Scilit:
- RENEB intercomparisons applying the conventional Dicentric Chromosome Assay (DCA)International Journal of Radiation Biology, 2016
- A Novel Technology for Multiplex Gene Expression Analysis Directly from Whole Blood Samples Stabilized at Ambient Temperature Using an RNA-Stabilizing BufferThe Journal of Molecular Diagnostics, 2015
- Laboratory Intercomparison of the Dicentric Chromosome Analysis AssayRadiation Research, 2013
- Triage and Treatment Tools for Use in a Scarce Resources-Crisis Standards of Care Setting After a Nuclear DetonationDisaster Medicine and Public Health Preparedness, 2011
- Radiation Dose Prediction Using Data on Time to Emesis in the Case of Nuclear TerrorismRadiation Research, 2009
- American Burn Association Practice Guidelines Burn Shock ResuscitationJournal of Burn Care & Research, 2008
- Medical Treatment of Radiological Casualties: Current ConceptsAnnals of Emergency Medicine, 2005
- Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working GroupAnnals of Internal Medicine, 2004